Ara-290

Ara-290 is a small peptide derived from a portion of the erythropoietin (EPO) molecule and has been investigated for potential tissue-protective and anti-inflammatory effects.

Ara-290 is designed to engage a so-called tissue-protective EPO receptor complex without stimulating classic erythropoietic pathways, aiming to separate protective effects from red blood cell production.

Clinical research has focused on neuropathic pain, small fiber neuropathy, and related conditions. Regulatory approvals, if present, are region- and product-specific.

This page states its uncertainty plainly rather than resolving it in either direction. Neither "ARA-290" nor "cibinetide" appears anywhere in the text or index of the 2026 WADA Prohibited List. No named entry settles the question. What follows is why the category nonetheless appears to reach it.

The category is named by receptor, and it is Ara-290's receptor. Sub-section S2.1.5 of the 2026 List reads, in full: "Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO)." That is not a generic heading — "innate repair receptor" is a specific term of art, coined in the literature that produced Ara-290 itself. Collino and colleagues describe "a heterodimer receptor complex composed of EPOR and β common receptor (βcR) subunits, termed the innate repair receptor (IRR)," and identify Ara-290 as its defining ligand: "EPO derivatives have been developed which selectively activate the IRR without interacting with the EPOR homodimer. The latest generation of specific ligands of the IRR includes an 11 amino acid peptide modeled from the three dimensional structure of the EPO in the region of helix B called pyroglutamate helix B surface peptide (pHBSP; ARA-290)" (Collino et al., Pharmacol Ther 2015). A Phase 2 trial report puts it in one line: Ara-290 "interacts selectively with the innate repair receptor that mediates tissue protection" (Brines et al., Mol Med 2015). If a category prohibits agonists of a named receptor, a peptide engineered to be a selective agonist of that receptor is the paradigm case, not an edge case.

The reach is reinforced by the class preamble. S2.1 opens: "The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited," followed by "Including, but not limited to." Ara-290 satisfies both limbs — it is engineered from the EPO molecule (similar chemical structure) and selectively activates the IRR (similar biological effect).

"It doesn't raise hematocrit" is the weakest possible argument here. The intuitive defence is that Ara-290 is non-erythropoietic, so it cannot be an erythropoiesis-affecting agent. That argument fails on the face of the list, because the two substances S2.1.5 does name share exactly that property. Carbamylated EPO is described in the pharmacology literature as "the first rHuEPO derivative that lacks erythropoietic activity but retains tissue protection properties" (Chattong et al., Br J Pharmacol 2013). WADA created S2.1.5 specifically to capture non-erythropoietic EPO derivatives. Being non-erythropoietic is the entry criterion for the sub-section, not an exemption from it.

For an athlete subject to testing, the practical position is straightforward even though the classification is not: a substance whose defining pharmacological description matches a prohibited category name, with no approved indication to support a therapeutic use exemption, is not a compound to use on the assumption that an unnamed substance is a permitted one. See EPO for the parent molecule and the rest of the S2.1 class.

Detailed risk information should be obtained from product labeling and up-to-date trial reports.

Ara-290 (Cibinetide) is a short-acting peptide requiring daily administration for neuropathic indications.

This dosage is derived from Phase 2 clinical trials for sarcoidosis-associated neuropathy.

ARA-290 was studied as a single-agent injectable — intravenous in the earliest trial, subcutaneous in later ones — and gray-market versions are sold as lyophilized powder for reconstitution. No combination products have been studied.

Clinical and preclinical studies have examined pain scores, nerve fiber measures, and inflammatory markers. The overall evidence base remains relatively specialized.

For deeper dives on this peptide, see:

• Ara-290 benefits and areas of interest
• Ara-290 side effects and safety context
• Ara-290 dosing concepts (educational)
• Ara-290 research and evidence overview

Is ARA-290 the same as EPO? No. It is an 11-amino-acid fragment engineered from one helix of erythropoietin, designed to trigger EPO's tissue-repair signaling without stimulating red-blood-cell production. It is not useful for blood doping and did not raise blood counts in trials.

What has ARA-290 actually been tested for? Small-fiber neuropathy — in sarcoidosis and in type 2 diabetes. Three small randomized trials (the largest with 64 participants, none longer than 28 days of dosing) reported improved neuropathy symptoms and regrowth of corneal nerve fibers.

Is ARA-290 approved anywhere? No. Development under the name cibinetide never progressed to large phase 3 trials, and no regulatory submission was completed. Anything sold as ARA-290 is an unapproved research chemical.

Is a higher dose more effective? Not in the published data. In the dose-ranging trial, 4 mg daily improved nerve-fiber measures while 8 mg did not — a non-linear dose response that argues against "more is better" assumptions.